Somewhat Positive News Coverage Somewhat Unlikely to Affect Diplomat Pharmacy (DPLO) Share Price

News coverage about Diplomat Pharmacy (NYSE:DPLO) has been trending somewhat positive this week, according to Accern Sentiment. Accern ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Diplomat Pharmacy earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 47.7928905076648 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

These are some of the news stories that may have impacted Accern’s scoring:

Shares of Diplomat Pharmacy (NYSE DPLO) opened at 16.20 on Friday. The company has a market capitalization of $1.10 billion, a PE ratio of 88.52 and a beta of 0.66. Diplomat Pharmacy has a one year low of $12.25 and a one year high of $34.80. The stock has a 50 day moving average price of $15.43 and a 200 day moving average price of $15.74.

Diplomat Pharmacy (NYSE:DPLO) last issued its quarterly earnings results on Monday, August 7th. The company reported $0.25 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.15 by $0.10. The firm had revenue of $1.13 billion for the quarter, compared to analyst estimates of $1.14 billion. Diplomat Pharmacy had a net margin of 0.27% and a return on equity of 7.97%. Diplomat Pharmacy’s quarterly revenue was up 3.5% compared to the same quarter last year. During the same period last year, the company posted $0.23 EPS. On average, equities research analysts predict that Diplomat Pharmacy will post $0.75 earnings per share for the current year.

Several equities research analysts have recently issued reports on DPLO shares. Barclays PLC set a $20.00 target price on Diplomat Pharmacy and gave the stock a “buy” rating in a report on Tuesday, May 9th. Needham & Company LLC started coverage on Diplomat Pharmacy in a report on Friday, July 21st. They issued a “buy” rating and a $19.75 target price on the stock. TheStreet raised Diplomat Pharmacy from a “d+” rating to a “c-” rating in a report on Thursday. Zacks Investment Research raised Diplomat Pharmacy from a “sell” rating to a “hold” rating in a report on Wednesday. Finally, BidaskClub cut Diplomat Pharmacy from a “buy” rating to a “hold” rating in a report on Thursday, June 29th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and two have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $17.89.

TRADEMARK VIOLATION WARNING: This news story was reported by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://transcriptdaily.com/2017/08/13/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-diplomat-pharmacy-dplo-share-price.html.

About Diplomat Pharmacy

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Insider Buying and Selling by Quarter for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply